Edwards Lifesciences Corporation
EW
$81.83
$0.670.83%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.53B | 1.41B | 1.39B | 1.35B | 1.37B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.53B | 1.41B | 1.39B | 1.35B | 1.37B |
| Cost of Revenue | 344.40M | 301.60M | 292.20M | 262.90M | 275.50M |
| Gross Profit | 1.19B | 1.11B | 1.09B | 1.09B | 1.09B |
| SG&A Expenses | 502.00M | 465.70M | 491.30M | 421.40M | 447.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -21.30M | -19.10M | -22.70M | 22.40M | -- |
| Total Operating Expenses | 1.10B | 1.00B | 1.03B | 960.10M | 994.80M |
| Operating Income | 430.90M | 409.90M | 353.90M | 394.30M | 374.60M |
| Income Before Tax | 400.20M | 433.90M | 390.10M | 402.80M | 384.00M |
| Income Tax Expenses | 64.30M | 70.30M | 45.10M | 40.70M | 20.00M |
| Earnings from Continuing Operations | 335.90M | 363.60M | 345.00M | 362.10M | 364.00M |
| Earnings from Discontinued Operations | -4.40M | -7.20M | 39.30M | 2.71B | 1.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.70M | 1.60M | 1.30M | 1.40M | 1.30M |
| Net Income | 333.20M | 358.00M | 385.60M | 3.07B | 366.30M |
| EBIT | 430.90M | 409.90M | 353.90M | 394.30M | 374.60M |
| EBITDA | 469.00M | 446.50M | 396.50M | 428.80M | 414.20M |
| EPS Basic | 0.57 | 0.61 | 0.65 | 5.14 | 0.61 |
| Normalized Basic EPS | 0.48 | 0.46 | 0.40 | 0.47 | 0.41 |
| EPS Diluted | 0.56 | 0.61 | 0.65 | 5.14 | 0.61 |
| Normalized Diluted EPS | 0.48 | 0.46 | 0.40 | 0.47 | 0.41 |
| Average Basic Shares Outstanding | 587.00M | 586.90M | 589.80M | 597.20M | 602.10M |
| Average Diluted Shares Outstanding | 587.90M | 587.80M | 590.50M | 598.10M | 604.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |